The Quantellect read.As of Nov 19, 2026, 14 active firms cover Marsh & McLennan Companies, Inc: 6 rate it Buy or better, 7 sit at Neutral, and 1 rate it Sell or worse, a neutral consensus. Targets are tightly clustered, $174.00 to $234.00, so the covering firms are broadly aligned. The average target of $204.29 is roughly in line with the current $204.28. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $3.58 next quarter toward $11.46 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS14 active firms
Neutral
Strong Buy17%
Buy536%
Neutral750%
Sell17%
Strong Sell00%
Based on 14 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$204.29
+0.0% upside
Average target across 14 active firms as of Nov 19, 2026 vs $204.28 current
Highest Target$234.00
Average Target$204.29
Lowest Target$174.00
Detailed analyst forecasts for MRSH
Showing 1–14 of 14 named analysts shown · 14 active firms in the rating projection
As of Nov 19, 2026, 6 of 14 active firms rate MRSH a Buy (7 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
MRSH EPS & revenue forecast
EPS · NEXT QUARTER
$3.58
Range $3.47 – $3.68 · 21 analysts · +9% YoY
Next period, 21 analysts expect Marsh & McLennan Companies, Inc. to earn $3.58 a share (range $3.47 – $3.68), versus $3.29 a year earlier. Full-year consensus is $10.49, growing to $11.46 the year after.
REVENUE · NEXT QUARTER
$8.0B
Range $7.9B – $8.1B · 21 analysts · +5% YoY
Revenue is expected to reach $8.0B (range $7.9B – $8.1B), +4.7% year-over-year. Full-year consensus is $28.7B, rising to $30.1B next year.
Top analysts covering Marsh & McLennan Companies, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MRSH.
#1
Alex Scott
Barclays · Rank #38
Buy
$206.00+0.8% to target
Overall win rate
58%
+ Follow
#2
Elyse Greenspan
Wells Fargo · Rank #85
Neutral
$197.00-3.6% to target
Overall win rate
57%
+ Follow
#3
C. Gregory Peters
Raymond James · Rank #240
Buy
$225.00+10.1% to target
Overall win rate
52%
+ Follow
#4
Meyer Shields
Keefe, Bruyette & Woods · Rank #259
Neutral
$201.00-1.6% to target
Overall win rate
44%
+ Follow
#5
Paul Newsome
Piper Sandler · Rank #272
Neutral
$182.00-10.9% to target
Overall win rate
50%
+ Follow
MRSH stock forecast FAQ
What is MRSH's average 12-month price target?+
The 14 active firms with a live target average $204.29 for Marsh & McLennan Companies, Inc. over the next 12 months, ranging from a $234.00 high to a $174.00 low, as of Nov 19, 2026.
Is MRSH stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 14 active firms as of Nov 19, 2026, 6 rate it Buy or Strong Buy, 7 rate it Neutral, and 1 rate it Sell or Strong Sell.
What are the highest and lowest price targets for MRSH?+
The Street-high target is $234.00 (Evercore ISI Group), and the Street-low is $174.00 (B of A Securities). The average of all 14 active-firm targets is $204.29.
How many active Wall Street firms cover MRSH?+
14 active firms have a recognized rating on Marsh & McLennan Companies, Inc. as of Nov 19, 2026, and 14 active firms carry a live 12-month price target.
Who is the most accurate analyst covering MRSH?+
Among analysts who currently cover MRSH, Alex Scott of Barclays has the strongest overall Quantellect track record (Rank #38). Their current call is Buy with a $206.00 target.
What is Marsh & McLennan Companies, Inc.'s projected EPS for next quarter?+
The consensus estimate is $3.58 per share (range $3.47 – $3.68) across 21 analysts. Full-year EPS is projected at $10.49, rising to $11.46 the following year.
How much revenue is Marsh & McLennan Companies, Inc. expected to report next quarter?+
Consensus revenue is $8.0B (range $7.9B – $8.1B). Full-year revenue is projected at $28.7B, growing to $30.1B next year.
Have analysts been upgrading or downgrading MRSH lately?+
As of Nov 19, 2026, 6 of 14 active firms rate MRSH a Buy (7 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MRSH calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.